A safety study of PF-08046044/SGN-35C in adults with advanced cancers
This research study is called a 'safety study' and is looking into a new medicine known as PF-08046044/SGN-35C. It's for adults who have advanced cancers, specifically certain types of lymphoma, such as diffuse large B-cell lymphoma, anaplastic large-cell lymphoma, Hodgkin disease, and peripheral T-cell lymphoma. This is the very first time this medicine will be given to people, so the main goal is to check its safety and see how the body reacts to it. The study will help doctors learn more about this new treatment and if it could be a useful option in the future for people with these conditions.
At a glance
What is this study about?
You might have heard about 'clinical trials' or 'research studies'. They are how doctors and scientists test new medicines or treatments to see if they are safe and if they work. This particular study is looking at a new medicine called PF-08046044/SGN-35C. It's for adults who have already been diagnosed with certain advanced cancers, including different types of lymphoma. These are conditions where abnormal cells grow in the lymphatic system, which is part of your body's immune system.
This is a 'Phase I' study, which means it's one of the earliest steps in testing a new medicine in humans. The main purpose of this first step is to carefully check if the medicine is safe. Researchers also want to find out how the medicine behaves in the body – for example, how much of it is needed and how long it stays in your system. They will be looking closely for any side effects.
Understanding how a new medicine works and if it's safe is incredibly important before it can be used more widely. Studies like this help to explore new ways to treat serious illnesses and potentially improve care for people in the future. We don't have all the answers yet about this new medicine, but this study is designed to gather that crucial first information.
Key takeaways
- This study is testing a new medicine for certain advanced lymphomas.
- It's an early-stage 'safety study' – the first time given to humans.
- The main aim is to check if the medicine is safe and how it works.
- Adults aged 18 and over with specific cancers can take part.
- Participation involves regular clinic visits for monitoring and tests.
- You can stop participating at any time if you wish.
Who may be eligible?
To join this study, you need to be an adult, aged 18 years or older. There is no upper age limit for taking part.
The study is for people who have been diagnosed with advanced cancers. Specifically, this includes certain types of lymphoma, such as diffuse large B-cell lymphoma, anaplastic large-cell lymphoma, Hodgkin disease, and peripheral T-cell lymphoma.
Both men and women can take part in this research. Besides your age and cancer type, there will be other specific health requirements and medical checks to make sure the study is safe for you and that you meet all the criteria.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with an advanced cancer, specifically a type of lymphoma (such as diffuse large B-cell, anaplastic large-cell, Hodgkin disease, or peripheral T-cell)?
- Are you willing to attend regular clinic appointments and have medical tests?
- Are you able to understand and sign an informed consent form?
What does participation involve?
If you decide to take part in this study, you will be given the new medicine, PF-08046044/SGN-35C. This will involve regular visits to the clinic where you'll have various assessments. These will likely include blood tests, physical examinations, and possibly scans or other tests to monitor how the medicine is affecting your body and to check for any side effects. You'll be closely monitored throughout the study by the medical team. The total duration of your involvement will depend on the study plan, which includes receiving the medicine and then follow-up appointments to track your health after treatment. The exact schedule of visits and tests will be explained to you in detail.
Potential risks and benefits
Locations (5)
- —UnverifiedFrance
- —UnverifiedSpain
- —UnverifiedDenmark
- —UnverifiedGermany
- —UnverifiedItaly
Common questions
What is the main goal of this study?
The main goal is to check if the new medicine, PF-08046044/SGN-35C, is safe for people and to see how it works in the body for the first time.
Who can take part in this study?
Adults aged 18 and over who have certain types of advanced lymphoma can be considered for this study. Both men and women are welcome.
Will I get the new medicine if I join?
Yes, if you're eligible and choose to take part, you will receive the new medicine, PF-08046044/SGN-35C, as part of the study.
What kind of tests will I have?
You will have regular tests like blood tests, physical exams, and possibly scans to monitor your health and how the medicine affects you.
Can I leave the study if I change my mind?
Yes, you are free to leave the study at any time without giving a reason, and it won't affect your future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.